Triacetyldiphenolisatin

Summary

Triacetyldiphenolisatin (CHEMBL1909288) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 443.4 Da · C26H21NO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909288
Name	Triacetyldiphenolisatin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	29321
Molecular formula	C26H21NO6
Molecular weight	443.4
InChIKey	JPGUEMQIAGJQSJ-UHFFFAOYSA-N

SMILES: CC(=O)N1C2=CC=CC=C2C(C1=O)(C3=CC=C(C=C3)OC(=O)C)C4=CC=C(C=C4)OC(=O)C

IUPAC name: [4-[1-acetyl-3-(4-acetyloxyphenyl)-2-oxoindol-3-yl]phenyl] acetate

Also known as: Phenisatin, Triacetyldiphenolisatin, Trisatin, triacetyldiphenolisatin, TRIACETYLDIPHENOLISATIN

Patent coverage: 18 distinct patent families (31 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 28 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).